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Postoperative pulmonary complications are common and may be associated with significant cost. Acute respiratory distress 
syndrome (ARDS), a life-threatening respiratory disease process characterised by hypoxaemia and reduced lung compliance, is 
one of the more serious pulmonary complications. The development of ARDS or the related entity of lung injury is associated 
with prolonged hospitalisation, ventilation, and time spent in intensive care, and profoundly increases the risk of mortality and 
significant morbidity. Patients with, or at risk of ARDS and lung injury, must be identified, optimised and managed with sound 
intraoperative principles (particularly ventilation and fluid management) – with the specific aim of limiting harm. This review 
will focus on the diagnosis, pathophysiology, prevention and management of ARDS and lung injury in the perioperative period.
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Introduction
Pulmonary complications after surgery are common and are 
associated with significant cost. These complications lengthen 
hospitalisation, ventilation, and time spent in intensive care, and 
profoundly increase the risk of mortality and significant 
morbidity. Acute respiratory distress syndrome (ARDS), a life-
threatening respiratory disease process characterised by 
hypoxaemia and reduced lung compliance,1,2 is one of the more 
serious postoperative pulmonary complications. In its severe 
form, ARDS carries a mortality rate of 45%.1,3 This concise review 
will focus on the diagnosis, pathophysiology, prevention and 
management of ARDS and the related entity of lung injury. The 
aim is to provide a broad overview of a complex clinical area.
Perioperative mechanical ventilation is one of the primary risk 
factors for the development of postoperative pulmonary 
complications; as many as one in four patients with normal lungs 
will develop some form of lung injury following mechanical 
ventilation.2 In patients with lung injury or ARDS, further lung 
injury risk with mechanical ventilation is significantly greater. 
However, much of this damage can be attenuated by using 
appropriate ventilation strategies.
Pathophysiology
The pathophysiological mechanisms of ARDS vary depending on 
the causative pathology, but several common inflammatory 
pathways that subsequently cause alveolar damage are involved. 
These inflammatory processes cause endothelial damage, 
disrupt normal protective barriers, inhibit surfactant production 
and function, impair coagulation, and inhibit normal alveolar 
immunological responses.4,5 Increased vascular permeability and 
damage to the pulmonary microvasculature results in fluid and 
neutrophil leakage into alveolar and interstitial tissue.6 The result 
is impaired gas exchange due to damaged alveolar-capillary 
membranes, and the two hallmark features of ARDS: hypoxaemia 
and reduced lung compliance.1 These lung changes are rarely 
homogenous and result in areas of disease interspersed with 
normal lung units. The stretching at the interface of diseased and 
healthy lung also causes excessive shear stress and perpetuates 
the release of inflammatory mediators and exacerbates local and 
systemic inflammation.
Diagnostic criteria
In 2012 the Berlin Definitions replaced the 1994 American-
European Consensus Conference (AECC) definition of ‘acute lung 
injury’ (ALI).1,7 The term ALI was discarded and the distinction 
between primary and secondary ALI (largely related to onset 
time) was integrated into a new ARDS definition. The Berlin 
Definitions, compiled by the European Society of Intensive Care 
Medicine and endorsed by the American Thoracic Society and 
the Society of Critical Care Medicine, recognise three stages of 
severity based on the PaO2/FiO2 ratio.
8 Four factors are involved 
in making the diagnosis:
(a)  Timing – onset over less than seven days;
(b)  Chest x-ray (or computerised tomography [CT] scan) 
changes – bilateral opacification not explained by alter-
native lung pathology;
(c)  Origin of oedema – must not be fully explained by cardiac 
failure or fluid overload, and an objective assessment 
(cardiac ultrasound) should be performed if there is 
uncertainty;
(d)  Severity of hypoxaemia, graded according to PF ratio 
(paO2 in mmHg), with a minimum positive end-expiratory 
pressure (PEEP) of 5 cm H2O [mild (200–300), moderate 
(100–200) or severe (< 100)].1
Anaesthetic management strategies for 
patients with ARDS
Several advancements have improved ARDS outcomes. These 
include better ventilation strategies and care bundles, transfusion 
and fluid management, and early appropriate management of 
sepsis.9−18 Patients with, or at risk of ARDS, must be identified, 
optimised and managed with sound intraoperative principles 
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(particularly ventilation and fluid management) – with the 
specific aim of limiting harm.
Anaesthesiologists caring for patients with, or at risk of ARDS, 
should aim to:
(1)  Provide optimal ventilation and anaesthesia without 
compromising the cardiovascular system;
(2)  Ventilate patients with lung protective strategies to limit 
inflammatory processes;
(3)  Avoid unnecessary intravenous fluids that contribute to 
extravascular lung water accumulation; and
(4)  Promote recovery and postoperative mobilisation.
Despite a lack of data showing that these principles improve 
outcomes in healthy patients, it seems prudent to adopt these 
strategies in all ventilated perioperative patients.
A. Preoperative management
Preoperative objectives include the identification of patients at 
risk for developing ARDS (using general risk factors and scoring 
systems) and optimisation of these patients where possible. 
These measures are outlined below.
(1)  Identification of general risk factors for developing ARDS 
(Table 1).
(2)  Risk prediction scores for ARDS.
(a)  Several ARDS risk prediction models exist and vary from 
specific surgical populations (predominantly 
cardiothoracic)19−25 to general surgical patients.26,27 The 
Surgical Lung Injury Prediction 2 model (SLIP-2) is a 
mathematical model that predicts patients at risk of 
developing early postoperative lung injury (Table 2). The 
score performed well in distinguishing patients that 
develop early lung injury from those that do not (AUC 
[95% CI], 0.84 [0.81, 0.88]).27 Kor et al.27 identified nine 
independent ARDS predictors.
(b)  The Lung Injury Prediction (LIP) Score is an alternative 
model initially developed for all patients, and validated in 
surgical critical care patients.28,29 The LIP Score performed 
well in this surgical population (receiver operating 
characteristic [ROC] area under the curve of 0.79, with 
good calibration).
(c)  More recently, early oxygen saturation to fraction of 
inspired oxygen ratio (within 6 hours of hospital 
admission) has been shown to be an independent 
indicator of ARDS development in patients at risk.30
(d)  Several biomarkers of alveolar epithelial injury, vascular 
endothelial injury and increased coagulation in patients 
with ARDS correlate with morbidity and mortality.8,18,31 
Biomarker panels may also help differentiate severe 
sepsis-induced ARDS from trauma-induced lung 
injury.18,32−34 However, their clinical utility for diagnosis 
and prognostication is unproved.
(3)  Optimisation
(a)  Early recognition of underlying respiratory infections and 
identification of causative pathogens is an essential part 
of preoperative management. Consideration should be 
given to possible bacterial, fungal and viral infections. 
Early empiric antibiotic therapy is advisable in overtly 
septic patients, with subsequent de-escalation to directed 
therapy in response to culture results.
(b)  Bedside lung ultrasound may offer additional diagnostic 
information as shown in a recent pilot study combining 
ultrasound with SpO2/FiO2 ratios.35 It is also a useful 
adjunct to help differentiate ARDS from cardiogenic 
pulmonary oedema.36
(c)  Routine approaches to reduce gastric aspiration and 
ventilator-associated pneumonia should be employed.
B. Intraoperative management
General anaesthesia has several negative consequences on the 
respiratory system:
(i)  Basal atelectasis (due to positioning, high inspired FiO2, 
and reduced functional residual capacity).
(ii)  Loss of muscle tone and subsequent decreased nega-
tive pressure lung expansion.
(iii) Decreased minute ventilation.
(iv) Closing capacity nearing functional residual capacity.
(v)  Volatile anaesthetic-induced inhibition of hypoxic pul-
monary vasoconstriction leading to increased intrapul-
monary shunting.
(vi)  Increased alveolar dead space ventilation due to ate-
lectasis and alterations in perfusion characteristic in 
the supine and anaesthetised position.
(vii)  Blunting of the normal responses to hypercarbia.37
Ventilating patients with ARDS undergoing general anaesthesia 
adds even more complexity.
Table 1: General risk factors for developing ARDS1
Notes: ARDS = acute respiratory distress syndrome; TRALI = transfusion-associated 
acute lung injury.
Direct risk factors Indirect risk factors
Pneumonia Non-pulmonary sepsis
Aspiration of gastric contents Major trauma
Inhalational injury Pancreatitis
Pulmonary contusion Severe burns
Pulmonary vasculitis Non-cardiogenic shock
Drowning Drug overdose
Multiple transfusions or TRALI
Table 2: Independent ARDS predictors used in the Surgical Lung Injury 
Prediction 2 model (SLIP-2)
Notes: ARDS = acute respiratory distress syndrome; FiO2 = fraction of inspiratory 
oxygen; SpO2 = blood oxygen saturation.
SLIP-2 model predictors of ARDS27
Sepsis




Admission location other than home
Increased respiratory rate (20–29 and > 30 breaths/min)
FiO2 greater than 0.35
SpO2 less than 95%
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(1)  Ventilation
Mechanical forces generated by positive pressure ventilation 
contribute to ventilator-induced lung injury and ARDS. This is 
particularly severe at the interface between normal lung units 
and diseased lung units. Management strategies attempt to limit 
the amount of stretching, strain and biotrauma generated at 
these interfaces.38 Newer concepts in reducing ventilator-
induced lung injury include minimising alveolar damage through 
the reduced transfer of energy to at-risk lung units. Recent focus 
has moved away from traditional concepts such as barotrauma 
and volutrauma, towards mechanical and driving power. Driving 
pressure (the plateau pressure minus PEEP) is once such theory 
that explores the relationship between reduced energy transfer 
and improved mortality in perioperative and ARDS patients. 
Although further research is required, it is a promising field that 
is supported by both physiological explanations and 
retrospective data analysis. Mechanical power is a concept that 
attempts to unify multiple ventilator-related causes of lung 
injury into a single variable.39 Ventilator indices such as tidal 
volume, driving pressure, flow, PEEP and respiratory rate are 
expressed in an equation that quantifies mechanical power, 
measured in joules. Initial experimental work has confirmed that 
with rising power there is a higher likelihood of developing 
ventilator-induced lung injury (VILI).40 Driving power and 
mechanical power are increasingly being suggested as new 
targets in ventilator strategies aimed at reducing VILI. A detailed 
discussion is beyond the scope of this review, but further reading 
is advised in this area.41
(a)  FiO2: The majority of evidence from ICU patients now rec-
ommends targeting an FiO2 resulting in a SpO2 of be-
tween 88 and 95%.36 Additional research is needed to 
determine the net benefits related to potential lung tox-
icity caused by unnecessarily high concentrations of in-
spired oxygen (such as diffuse alveolar damage, direct 
airway injury, increasing dead space), and the potential 
benefits on neurocognitive outcomes when targeting 
normoxaemia.42
(b)  Positive end expiratory pressure (PEEP): Selecting the ide-
al PEEP is challenging. PEEP maintains open alveolar 
units, and potentially avoids repeated opening and clos-
ing of alveoli and interfaces between collapsed and open 
units. This minimises sheer forces and biotrauma experi-
enced in an unevenly atelectatic lung. However, in heter-
ogeneously affected lungs, where PEEP may be beneficial 
in some lung units, excessive PEEP may result in overdis-
tension. It may be reasonable to apply a PEEP of 10 cm-
H2O at the start of ventilation.36,43−45
(c)  Tidal volumes (TV): Increasing data support low tidal vol-
ume ventilation in patients with established ARDS. 
Despite a lack of randomised control trials showing a re-
lated decrease in postoperative pulmonary complica-
tions,43 low tidal volumes are likely to reduce the shear 
stresses imposed by PPV within diseased lung regions, 
and this approach has the potential to improve out-
comes.36,46 Increasing importance is being placed on the 
measurement and control of the driving pressure (ratio 
between tidal volume and compliance, or plateau pres-
sure minus PEEP).47−49 Tidal volumes of 6–8 ml/kg (impor-
tantly, ideal ventilatory body weight) should be targeted, 
with a low plateau pressure (< 16 cm H2O), and preferably 
a low ΔP (< 13 cm H2O). Tidal volumes of 4–5 ml/kg or less 
should be targeted for one lung ventilation. If achieving 
ventilator targets described above does not allow nor-
malisation of paCO2, permissive hypercapnia in the ab-
sence of raised intracranial pressure or severe right heart 
failure should be allowed. The physiological benefits of 
hypercapnia include a rightward shift of the oxygen-hae-
moglobin dissociation curve, increased cardiac output 
and an anti-inflammatory action.50
(d)  Mode of ventilation: The mode of ventilation does not ap-
pear to influence ARDS outcomes.51,52
(e)  Recruitment manoeuvres: Recruitment manoeuvres are 
controversial, being recommended by some and avoided 
by those supporting ‘intraoperative permissive atelecta-
sis’.45,53 This new concept suggests recruitment manoeu-
vres should not be routine, particularly in severe ARDS. 
Recruitment manoeuvres may also be associated with sig-
nificant haemodynamic instability due to effects on right 
ventricular preload and afterload. Recommendations sup-
port individualised practice and avoidance of unnecessary 
attempts to expand lung units and the worsening of bio-
trauma and atelectrauma.53 The benefit of recruitment 
manoeuvres on patient outcome remain inconclusive,54 
and, as a recent publication suggests, may even increase 
mortality in patients with moderate to severe ARDS.55
(f)  Fluid management:
(i)  Although maintaining adequate tissue perfusion is impor-
tant, excess intravenous fluid potentially worsens hypox-
aemia, as leakage through a dysfunctional endothelial 
lung barrier increases extravascular lung water. 
Intravenous fluids should be given judiciously, guided by 
regular and repeated volume assessments and assess-
ment of fluid responsiveness. Dynamic markers of fluid 
responsiveness are superior to static markers and should 
be incorporated in the routine assessment of periopera-
tive patients. Xiaoming et al. demonstrated that a large 
positive net fluid balance – independent of ventilator set-
tings, plasma transfusions and severity of disease – was a 
risk factor for ARDS.56
(ii)  Blood product transfusions (red blood cells, plasma and 
platelets) have been identified as risk factors for ARDS. In 
the ICU and when possible in the operating room, a re-
strictive transfusion strategy with a haemoglobin trans-
fusion trigger of 7 g/dl and target haemoglobin of > 7 g/dl 
should be used. Transfusion-related acute lung injury has 
been linked to plasma containing blood products (plate-
lets, fresh frozen plasma).57 While efforts in the devel-
oped world aim to screen for high-risk donors, this is 
usually not possible in the developing world.18,58,59
(2)  Anaesthetic choices
(a)  Inhalational anaesthetics: In animal models, volatile 
anaesthetic agents protect against the damage caused 
during ischaemic-reperfusion injury.60 The benefit may be 
multifactorial and includes protection against endotheli-
al glycocalyx degradation, ischaemic pre-conditioning, 
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(3)  Haemodynamics
(a)  Haemodynamic instability may occur during anaesthesia 
for ARDS. Potential causes are multifactorial and occur at 
least in part because of an interdependent functional rela-
tionship between the respiratory and cardiovascular sys-
tems. Right heart dysfunction or failure may result from 
pulmonary arterial hypertension secondary to hypoxic pul-
monary vasoconstriction, exacerbated by the negative ef-
fects of mechanical ventilation on the right side of the 
heart, i.e. increased pulmonary vascular pressure from 
PEEP and positive pressure ventilation. Ventricular interde-
pendence (interventricular septal shift that results from 
right ventricular failure and distension, impedes left ven-
tricular (LV) filling and therefore preload), may also induce 
systemic hypotension. Increased pleural pressure may re-
duce venous return, especially in hypovolaemic patients. 
The poorly explained negative inotropic effects caused by 
the systemic inflammatory response may additionally ex-
acerbate cardiovascular system failure.
Increased LV diastolic pressure caused by intraventricular septal 
shift to the left side may increase pulmonary venous pressure, 
increasing capillary hydrostatic pressure and subsequent 
and even immune-modulating effects (inhibition of 
pro-inflammatory mediators including IL-8, IL-10, and 
TNF).8,61−66
(b)  There is little evidence to support one type of anaesthetic 
over another. Volatile anaesthetic agents do inhibit hy-
poxic pulmonary vasoconstriction, but carry potential 
advantages mentioned above. Intravenous agents, such 
as propofol, may worsen endothelial function when giv-
en in overdose, but this requires further research.67
(c)  There is little evidence to guide the choice of anaesthesia 
with a view to reducing the postoperative complications 
of ARDS. However, a general anaesthetic is likely to be 
appropriate for most ARDS patients, as management of 
PEEP and TV generally requires tracheal intubation. There 
is some evidence supporting the approach of a combined 
general anaesthetic and neuraxial technique for postop-
erative analgesia as it has been shown to decrease the 
incidence of postoperative pneumonia and respiratory 
failure – potential triggers for ARDS68 – although the ben-
efits of neuraxial block and postoperative epidural are 
not universal.69
Table 3: Modalities of therapy investigated for ARDS management
Notes: ARDS = acute respiratory distress syndrome, ECMO = extracorporeal membrane oxygenation, DNA = deoxyribonucleic acid.
Therapy Comment
Corticosteroids71−76 Identification of 21 microRNA has suggested steroid-sensitive and steroid-independent mechanisms 
in the development of ARDS. This may account for different responses to the use of corticosteroids in 
previous studies
Inhaled vasodilators36,77 Nitric oxide has vasodilatory effects on pulmonary vasculature, and improves arterial oxygenation, but its 
use has not demonstrated mortality or significant outcome benefits. Its use is complicated by high costs 
and increased renal dysfunction
Muscle relaxants36,78,79 Short-term use of muscle relaxation (up to 48 h) for patients with severe ARDS may reduce mortality 
risk and reduce ventilator-associated lung injury. This may be mediated by reducing transpulmonary 
pressures during mechanical ventilation and reducing oxygen consumption, but this strategy requires 
further investigation
 ECMO80 ECMO has shown promising results in uncontrolled reports of its use in the management of severe ARDS. 
The role of this expensive therapy in ARDS treatment and in the transport of those with severe ARDS 
requires further investigation
Aspirin81 Aspirin may have positive effects on platelets that play an active role in the development of ARDS. The 
Lung Injury Prevention Study with Aspirin, a phase II trial, did not show any outcome benefit
Aerosolised beta-2-agonists These agents have previously been effective in reducing pulmonary oedema by stimulating cyclic 
adenosine monophosphate-dependent alveolar fluid clearance. Initial studies demonstrated harm in 
patients with ARDS.82−84 However, a recent study showed favourable results with inhaled budesonide and 
formoterol. Patients had improved oxygenation, lower rates of acute respiratory failure and ARDS.85 This 
therapy appears promising
Keratinocyte growth factor and mesenchymal stem cells Keratinocyte growth factor (KGF) is expressed by mesenchymal cells and appears to promote cell repair 
via several mechanisms including stimulating type-2 pneumocyte development, increased surfactant 
production, DNA repair, and improved alveolar fluid clearance.18,86,87 The effects of KGF may explain the 
possible benefits of mesenchymal stem cells in ARDS. Researchers are currently investigating the role of 
intravenous KGF in patients with ARDS, and the immunomodulating role of mesenchymal stem cells88
Surfactant Surfactant inhibition and degradation is an important contributor to the pathogenesis of ARDS. Although 
successful in neonates and infants, multiple large trials in adults failed to show improved clinical out-
comes, despite reports of transient improvements in oxygenation and lung function. There is a continued 
search for a better exogenous surfactant replacement therapy89,90
Beta-blockers The theoretical benefit of beta-blockers in ARDS involves suppression of the overstimulated sympathetic 
response that may negatively affect pulmonary vasculature.91 Some benefit has been demonstrated in a 
porcine endotoxin shock model; however, further RCTs are required to understand benefit92
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extravascular lung water extravasation.70 The authors of a recent 
review emphasise the importance of ensuring euvolaemia, 
without unnecessary use of intravenous fluid administration. 
Bedside echocardiography, transpulmonary thermodilution, and 
inotropic support may provide additional monitoring 
information. Right ventricular ventilation protection strategies 
include minimising driving pressures, providing PEEP and 
ensuring adequate oxygenation. 70
Questions and future developments
Table 3 outlines several potential new strategies based on 
putative pathophysiological mechanisms for the management 
of ARDS. None have been shown to provide a definitive clinical 
benefit.
Prone positioning may benefit oxygenation due to the 
heterogenous atelectasis and consolidation seen in ARDS. 
Despite mortality benefit in the PROSEVA and other trials, its use 
in the perioperative period is unrealistic in most circumstances.93
Conclusion
Lung injury is a common pathology facing anaesthesiologists and 
accounts for significant postoperative pulmonary complications. 
Pulmonary and systemic complications can possibly be limited with 
appropriate ventilatory, haemodynamic and preoperative and 
postoperative critical care management bundles. New research is 
exploring multiple approaches to preventing and treating ARDS. 
These include optimisation of mechanical ventilation settings to 
minimise injury from positive pressure ventilation (pressures and 
volumes), pathophysiological mechanisms (inflammatory 
mediation), and supportive care (fluid therapy), and even alternative 
methods of respiratory support (ECMO).
Summary and learning points
(1)  Anaesthesiologists can play a potentially important role in 
preventing ARDS occurring postoperatively by applying 
preventive strategies, and minimising the complications 
of mechanical ventilation in patients with ARDS present-
ing for operation.
(2)  ARDS management strategies should be implemented 
throughout the preoperative, intraoperative and postop-
erative periods.
(3)  Ventilation goals in patients with ARDS presenting for an-
aesthesia should include: minimise FiO2 to maintain SpO2 
above 88%; appropriate PEEP to avoid atelectasis, but suffi-
cient to prevent shear stress; consider lowering PEEP if the 
driving pressure is high, particularly if increasing PEEP in-
creases driving pressure, or there are other signs of overdis-
tension present; maintain low tidal volumes (6 ml/kg ideal 
body weight); a plateau pressure < 16 cmH2O (maximum 30 
cmH2O); and a low ΔP (< 13 cm H2O), even if the resulting 
low TV requires permissive hypercapnia.
(4)  Avoid excessive intraoperative transfusion with goal of 
targeting 7 g/dl in the postoperative ICU period.
(5)  Volatile anaesthetics may provide a theoretical protective 
function, despite the negative effects on hypoxic pulmo-
nary vasoconstriction.
(6)  Haemodynamic stability should be achieved though con-
tinuous volume status assessment and judicious inotropic 
therapy. Utilisation of bedside investigations such as echo-
cardiography, and transpulmonary thermodilution/cardi-
ac output monitoring may provide additional guidance for 
fluid and vasopressor management.
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